Pharmaceutical industry

Ottawa delays drug-pricing changes a third time, citing COVID-19 pandemic

Drug makers want another delay for new pricing regulations from Ottawa

Canadian maker of promising mRNA COVID-19 vaccine looks to test it against Pfizer in new trial

Bausch Health selling stake in Egypt’s Amoun for $740-million

A booster shot for Big Pharma’s chronic productivity condition: give up sooner

EU regulators team up with U.S. and U.K. on pharmaceutical mergers

McKinsey’s top executive voted out as consulting firm faces reckoning over opioid crisis

Bausch Health shareholder pushes for completion of eye-care spinoff by end of 2021

GSK forecasts dip in profit but says plan to split business still on track

Investors flock to Canadian device maker Sernova hoping to transform how diabetes is treated

Bausch Health expects 2020 revenue to exceed previous guidance

Regulations to lower drug prices in Canada delayed yet again after industry cites COVID-19 concerns

Merck signs $356-million U.S. supply deal for experimental COVID-19 treatment

Canopy Growth cuts ties with investment company Canopy Rivers

Newly approved treatment could save a young child in Edmonton with a rare disease. It costs $2.8-million per dose

Merck sells stake in vaccine developer Moderna

Ottawa blocks Trump plan to allow bulk U.S. import of cheaper prescription drugs from Canada

Trump makes late-term bid to lower prescription drug costs

Pharmaceutical industry offers Ottawa $1-billion to scrap pending drug pricing rules, documents show

Developing a coronavirus vaccine is just the first step – distribution presents a whole new challenge

Cardinal Health and AmerisourceBergen book billions in costs related to opioid lawsuits

McKesson says cost of opioid settlements could reach $21-billion

Britain starts accelerated review for AstraZeneca’s potential COVID-19 vaccine

U.S. to charge Teva with conspiring to raise prices of generic drugs, sources say

Johnson & Johnson buying Momenta Pharmaceuticals for around $6.5-billion

U.S. states reportedly seeking $26.4-billion from drug firms in opioid litigation

Chairman of China’s Sinopharm rules out high price for potential coronavirus vaccine